soul trial semaglutide ADA 2025: Oral Demonstrates Cardiovascular Benefits in SELECT Trial

That extra 0.4 mg might sound small, but for some patients it provides a meaningful bump in effectiveness, particularly those who responded well to each previous dose increase but still have weight to lose

Pet Gala is built for that visible, everyday confirmation of care

Read clinical review Evidence-based review of semaglutide (Ozempic) efficacy differences in South Asian populations, including pharmacogenomic factors, BMI thresholds, and clinical trial subgroup data

doi: 10.3390/nu13082831 30

Current medical guidance treats obesity as a chronic condition, and long-term or indefinite semaglutide use is considered appropriate for patients with ongoing obesity-related health conditions